DOW JONES23,719.37+285.80 1.22%
S&P 5002,789.82+39.84 1.45%
NASDAQ8,153.58+62.67 0.77%

CFRA Downgrades Regeneron Pharmaceuticals to Hold, Raises Price Target to $487

CFRA analyst Kevin Huang downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Buy to Hold and raises the price target from $460 to $487.

Benzinga · 03/04/2020 17:58

CFRA analyst Kevin Huang downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Buy to Hold and raises the price target from $460 to $487.